PICO Advisory Sub-Committee (PASC) – Applications considered

• 1785 – Dexcom ONE continuous glucose monitoring system for people with insulin dependent type 2 diabetes
• 1786 – FreeStyle Libre 2 continuous glucose monitoring system for people with insulin dependent type 2 diabetes, gestational diabetes and type 3c diabetes
• 1787 – Immunohistochemistry testing of solid tumour tissue to determine folate receptor alpha (FRa) expression status in adults with platinum-resistant ovarian cancer, to determine eligibility for treatment with PBS subsidised mirvetuximab soravtansine
• 1788 – ArteraAI Prostate Biopsy Assay for patients with localised prostate cancer
• 1789 – Computed tomography (CT) colonography for the detection of colorectal polyps and colorectal cancer

Consultation Input:

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.

Consultation for the December 2024 PASC meeting closes on Friday 8 November 2024.

Further information on MSAC’s consultation process is available on the MSAC website.